Eun Yang
Stock Analyst at Jefferies
(0.66)
# 3,717
Out of 4,711 analysts
47
Total ratings
37.93%
Success rate
-24.11%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $359.58 | +20.14% | 8 | Sep 23, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | $65 → $2 | $2.53 | -20.95% | 3 | Jun 17, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $1.85 | +332.43% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $9.56 | +182.43% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.95 | +57.89% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $26.49 | +24.58% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $4.23 | +561.94% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $22.47 | +20.16% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.54 | +175.59% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $2.87 | - | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.90 | +762.07% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $75 | $1.21 | +6,098.35% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $84 | $90.14 | -6.81% | 3 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.69 | +1,379.29% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $5.74 | - | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $17.16 | +103.96% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $263.38 | -16.47% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $38 → $31 | $15.52 | +99.74% | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.75 | +22,757.14% | 1 | Jul 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $146.47 | +111.65% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $92.57 | -13.58% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $359.58
Upside: +20.14%
Aerovate Therapeutics
Jun 17, 2024
Downgrades: Hold
Price Target: $65 → $2
Current: $2.53
Upside: -20.95%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $1.85
Upside: +332.43%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $9.56
Upside: +182.43%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.95
Upside: +57.89%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $26.49
Upside: +24.58%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $4.23
Upside: +561.94%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $22.47
Upside: +20.16%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.54
Upside: +175.59%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $2.87
Upside: -
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $2.90
Upside: +762.07%
Sep 22, 2022
Maintains: Buy
Price Target: $525 → $75
Current: $1.21
Upside: +6,098.35%
Aug 22, 2022
Maintains: Buy
Price Target: $78 → $84
Current: $90.14
Upside: -6.81%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.69
Upside: +1,379.29%
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $5.74
Upside: -
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $17.16
Upside: +103.96%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $263.38
Upside: -16.47%
Nov 3, 2017
Maintains: Hold
Price Target: $38 → $31
Current: $15.52
Upside: +99.74%
Jul 24, 2017
Initiates: Buy
Price Target: $400
Current: $1.75
Upside: +22,757.14%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $146.47
Upside: +111.65%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $92.57
Upside: -13.58%